SEE WHAT BIZENGRI® CAN DO

BIZENGRI is for adults with neuregulin 1 fusion–positive (NRG1+) pancreatic adenocarcinoma or NRG1+ non–small cell lung cancer (NSCLC) that has spread despite prior treatment or cannot be removed by surgery.

BIZENGRI works by decreasing signaling caused by NRG1 fusions

Why is targeting NRG1 fusions important?

  • A neuregulin 1 (NRG1) fusion occurs when the NRG1 gene joins with another gene
  • NRG1 fusions can signal cells to grow faster

BIZENGRI decreases the signal causing cells, including cancer cells, to grow and spread.

How are NRG1 fusions detected?

NRG1 fusions can only be detected using an advanced genomic test called next-generation sequencing, or NGS. NGS examines your genes in more detail to help find gene fusions like NRG1.

If you want to learn if an NRG1 fusion is causing your cancer, ask your doctor about having an RNA-based NGS test

BIZENGRI is the only medicine specifically approved to treat adults with NRG1+ pancreatic adenocarcinoma or NRG1+ NSCLC

There are no FDA-approved tests available for detecting NRG1 fusions.

BIZENGRI results

In a clinical trial, adult patients with advanced or metastatic NRG1+ NSCLC (64 patients) or pancreatic adenocarcinoma (30 patients) who had disease progression following standard-of-care treatment for their disease were treated with BIZENGRI.

The main goal of the trial was to see how many patients had their tumors shrink by at least 30% or disappear altogether

This trial also looked at how long patients were able to maintain the reduction in tumor size

Know what to expect with BIZENGRI treatment

See dosing and side effects

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BIZENGRI?

BIZENGRI may cause serious side effects, including:

  • Infusion-related, allergic and anaphylactic reactions. BIZENGRI may cause serious infusion-related and allergic reactions that can be life-threatening. Infusion-related reactions are also common during BIZENGRI treatment. Before each BIZENGRI infusion, your healthcare provider will give you medicines to help reduce your chance of getting infusion-related reactions. Your healthcare provider will monitor you for signs and symptoms during your infusion and for at least 1 hour after your first infusion and as needed. Tell your healthcare provider right away if you develop any of the following symptoms during or after your BIZENGRI infusion:
    • chills or shaking
    • nausea, vomiting, or diarrhea
    • fever
    • cough
    • sudden swelling of your face, tongue, throat, or troubled swallowing
    • throat tightness or discomfort
    • itching or rash
    • shortness of breath or wheezing
    • chest discomfort
    • feeling light-headed
    • dizziness
    • back or neck pain
    • feeling of numbness or tingling
  • Lung problems. BIZENGRI may cause serious lung problems that may be life-threatening. If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you develop any new or worsening symptoms of lung problems, including:
    • trouble breathing
    • shortness of breath
    • cough
    • fever
  • Heart problems that may affect your heart’s ability to pump blood. BIZENGRI may cause serious and life-threatening heart problems that may lead to death. Your healthcare provider will check your heart function before you start treatment with BIZENGRI and as needed during your treatment. Tell your healthcare provider right away if you develop any new or worsening symptoms of heart problems, including:
    • shortness of breath
    • coughing
    • tiredness
    • swelling of your feet, ankles or legs
    • irregular heartbeat
    • sudden weight gain
    • dizziness or feeling light-headed
    • loss of consciousness

Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with BIZENGRI.

Before receiving BIZENGRI, tell your healthcare provider about all your medical conditions, including if you:

  • have lung or breathing problems other than your lung cancer.
  • have or have had any heart problems.
  • are breastfeeding or plan to breastfeed. It is not known if BIZENGRI passes into your breast milk. Do not breastfeed during treatment and for 2 months after your last dose of BIZENGRI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.

What are the possible side effects of BIZENGRI?

BIZENGRI may cause serious side effects, including:

  • See “What is the most important information I should know about BIZENGRI?”

The most common side effects of BIZENGRI include:

  • diarrhea
  • muscle or bone pain
  • tiredness
  • nausea
  • shortness of breath
  • rash
  • constipation
  • vomiting
  • stomach-area (abdominal) pain
  • swelling of your breast, face, ankles or legs

The most common severe abnormal blood test results with BIZENGRI include:

  • increased blood levels of liver enzymes and bilirubin
  • decreased red blood cell counts and platelet counts
  • decreased blood level of sodium, magnesium, and phosphate
  • increase in the time that it takes your blood to clot

These are not all of the possible side effects of BIZENGRI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including BOXED WARNING.

What is BIZENGRI?

BIZENGRI is a prescription medicine used to treat adults who have: 

  • lung cancer called non-small cell lung cancer (NSCLC):
    • that has a neuregulin 1 (NRG1) gene fusion and cannot be removed by surgery or has spread to other parts of the body (advanced unresectable or metastatic), and
    • whose disease has worsened on or after prior cancer treatment.
  • pancreatic cancer called pancreatic adenocarcinoma:
    • that has a neuregulin 1 (NRG1) gene fusion and cannot be removed by surgery or has spread to other parts of the body (advanced unresectable or metastatic), and
    • whose disease has worsened on or after prior cancer treatment.

It is not known if BIZENGRI is safe and effective in children.

Please see full Prescribing Information, including BOXED WARNING.

Contact Us

For BIZENGRI product inquiries:
For BIZENGRI patient support:
  • 9 AM to 5 PM ET, Monday-Friday
LinkedIn logo
  • BIZENGRI® is a registered trademark of Merus N.V.
  • PARTNER THERAPEUTICS and are registered trademarks of Partner Therapeutics, Inc.
  • © 2025 Partner Therapeutics, Inc. US-BEN-2500011 03/25

Please read our Privacy Statement and updated Terms of Use. As described further therein, we use third-party cookies to improve the operation of our site. If you require further information and/or wish to disable cookies, please visit www.allaboutcookies.org.